Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5

Arthritis and Rheumatism

Volumn 52, Issue 2, 2005, Pages 627-636

  Vierboom, Michel P M ^a   Zavodny, Paul J ^b   Chou, Chuan Chu ^b   Tagat, Jayaram R ^b   Pugliese Sivo, Catherine ^b   Strizki, Julie ^b   Steensma, Ruo W ^b   McCombie, Stuart W ^b   Çelebi Paul, Liesbeth ^a   Remarque, Ed ^a   Jonker, Margreet ^a   Narula, Satwant K ^b   'T Hart, Bert ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; COLLAGEN TYPE 2; RECEPTOR BLOCKING AGENT; SCH X; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BODY WEIGHT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; RHEUMATOID ARTHRITIS; SOFT TISSUE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; FOLLOW-UP STUDIES; MACACA MULATTA; MALE; RECEPTORS, CCR5;

EID: 13444303844     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20850     Document Type: Article

References (51)

1. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000;95:3032-43.
2. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391:344-5.
3. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998;101:746-54.
4. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997;277:2005-7.
5. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999;96:6873-8.
6. Trebst C, Sorensen TL, Kivisakk P, Cathcart MK, Hesselgesser J, Horuk R, et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001;159:1701-10.
7. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-15.
8. Teleshova N, Pashenkov M, Huang YM, Soderstrom M, Kivisakk P, Kostulas V, et al. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid. J Neurol 2002;249:723-9.
9. Aust G, Sittig D, Steinert M, Lamesch P, Lohmann T. Graves' disease is associated with an altered CXCR3 and CCR5 expression in thyroid-derived compared to peripheral blood lymphocytes. Clin Exp Immunol 2002;127:479-85.
10. Simchen C, Lehmann I, Sittig D, Steinert M, Aust G. Expression and regulation of regulated on activation, normal T cells expressed and secreted in thyroid tissue of patients with Graves' disease and thyroid autonomy and in thyroid-derived cell populations. J Clin Endocrinol Metab 2000;85:4758-64.
11. Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, Okumura K. Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol 1999;11:553-9.
12. Wedderburn LR, Robinson N, Patel A, Varsani H, Woo P. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 2000;43:765-74.
13. Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001;98:39-45.
14. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, et al. Expression of IP-10/CXCL10 and MIG/ CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 2002;161:195-206.
15. Shadidi KR, Aarvak T, Henriksen JE, Natvig JB, Thompson KM. The chemokines CCL5, CCL2 and CXCL12 play significant roles in the migration of Th1 cells into rheumatoid synovial tissue. Scand J Immunol 2003;57:192-8.
16. Garred P, Madsen HO, Petersen J, Marquart H, Hansen TM, Freiesleben Sorensen S, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998;25:1462-5.
17. Zapico I, Coto E, Rodriguez A, Alvarez C, Torre JC, Alvarez V. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun 2000;1:288-9.
18. Barcellos LF, Schito AM, Rimmler JB, Vittinghoff E, Shih A, Lincoln R, et al, and the Multiple Sclerosis Genetics Group. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Immunogenetics 2000;51:281-8.
19. Ogata H, Takeya M, Yoshimura T, Takagi K, Takahashi K. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J Pathol 1997;182:106-14.
20. Barnes DA, Tse J, Kaufhold M, Owen M, Hesselgesser J, Strieter R, et al. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invest 1998;101:2910-9.
21. Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 1997;57:117-20.
22. Yang YF, Mukai T, Gao P, Yamaguchi N, Ono S, Iwaki H, et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol 2002;32:2124-32.
23. 'T Hart BA, Botman CA, Bakker NP. Induction of type II collagen-specific antibody production in blood lymphocyte cultures of rhesus monkeys (Macaca mulatta) with collagen-induced arthritis using the immobilized native antigen. Clin Exp Immunol 1991;83:375-8.
24. Bakker NP, van Erck MG, Otting N, Lardy NM, Noort RC, 't Hart BA, et al. Resistance to collagen-induced arthritis in a nonhuman primate species maps to the major histocompatibility complex class I region. J Exp Med 1992;175:933-7.
25. Bakker NP, van Erck MG, Botman CA, Jonker M, 't Hart BA. Collagen-induced arthritis in an outbred group of rhesus monkeys comprising responder and nonresponder animals: relationship between the course of arthritis and collagen-specific immunity. Arthritis Rheum 1991;34:616-24.
26. 'T Hart BA, Bank RA, de Roos JA, Brok H, Jonker M, Theuns HM, et al. Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. Br J Rheumatol 1998;37:314-23.
27. Chou CC, Fine JS, Pugliese-Sivo C, Gonsiorek W, Davies L, Deno G, et al. Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1β. Br J Pharmacol 2002;137:663-75.
28. Frevert CW, Wong VA, Goodman RB, Goodwin R, Martin TR. Rapid fluorescence-based measurement of neutrophil migration in vitro. J Immunol Methods 1998;213:41-52.
29. Ronday HK, te Koppele JM, Greenwald RA, Moak SA, de Roos JA, Dijkmans BA, et al. Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis. Br J Rheumatol 1998;37:34-8.
30. Terao K, Fujimoto K, Shimozuru Y, Nagai Y, Yoshikawa Y. Possible role of peripheral CD14 low monocytes in the development of collagen-induced arthritis in cynomolgus monkeys (Macaca fascicularis). Exp Anim 2001;50:9-18.
31. Brok HP, Tekoppele JM, Hakimi J, Kerwin JA, Nijenhuis EM, de Groot CW, et al. Prophylatic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clin Exp Immunol 2001;124:134-41.
32. Iannone F, Corrigall VM, Kingsley GH, Panayi GS. Evidence for the continuous recruitment and activation of T cells into the joints of patients with rheumatoid arthritis. Eur J Immunol 1994;24:2706-13.
33. Panayi GS. Targeting of cells involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 1999;38 Suppl 2:8-10.
34. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol 2002;80:497-505.
35. Ransohoff RM, Bacon KB. Chemokine receptor antagonism as a new therapy for multiple sclerosis. Expert Opin Investig Drugs 2000;9:1079-97.
36. Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, Okumura K. Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol 1999;11:553-9.
37. 'T Hart BA, Bontrop RE. The relevance of arthritis research in non-human primates. Br J Rheumatol 1998;37:239-42.
38. 'T Hart BA, Vervoordeldonk M, Heeney JL, Tak PP. Gene therapy in nonhuman primate models of human autoimmune disease. Gene Ther 2003;10:890-901.
39. Bakker NP, van Erck MG, Zurcher C, Faaber P, Lemmens A, Hazenberg M, et al. Experimental immune mediated arthritis in rhesus monkeys: a model for human rheumatoid arthritis? Rheumatol Int 1990;10:21-9.
40. Bakker NP, van Besouw N, Groenestein R, Jonker M, Hart LA. The anti-arthritic and immunosuppressive effects of cyclosporin A on collagen-induced arthritis in the rhesus monkey. Clin Exp Immunol 1993;93:318-22.
41. 'T Hart BA, Bakker NP, Jonker M, Bontrop RE. Resistance to collagen-induced arthritis in rats and rhesus monkeys after immunization with attenuated type II collagen. Eur J Immunol 1993;23:1588-94.
42. Anthony DD, Haqqi TM. Collagen-induced arthritis in mice: an animal model to study the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 1999;17:240-4.
43. Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001;103:407-16.
44. Holmdahl R, Bockermann R, Backlund J, Yamada H. The molecular pathogenesis of collagen-induced arthritis in mice: a model for rheumatoid arthritis. Ageing Res Rev 2002;1:135-47.
45. Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, 't Hart BA, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998;41:1481-8.
46. Hart BA, Bakker NP, Jonker M, Bontrop RE. Resistance to collagen-induced arthritis in rats and rhesus monkeys after immunization with attenuated type II collagen. Eur J Immunol 1993;23:1588-94.
47. Oldenburg HS, Rogy MA, Lazarus DD, van Zee KJ, Keeler BP, Chizzonite RA, et al. Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur J Immunol 1993;23:1889-94.
48. Shinkura H, Imazeki I, Yamazaki M, Oda Y, Kotoh M, Mihara M. In vivo blocking effects of a humanized antibody to human interleukin-6 receptor on interleukin-6 function in primates. Anticancer Res 1998;18:1217-21.
49. Mihara M, Kotoh M, Nishimoto N, Oda Y, Kumagai E, Takagi N, et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol 2001;98:319-26.
50. Fischer FR, Luo Y, Luo M, Santambrogio L, Dorf ME. RANTES-induced chemokine cascade in dendritic cells. J Immunol 2001;167:1637-43.
51. Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol 2001;167:5381-5.